Updated:
415 CAPITAL
415 Capital is a venture capital firm investing in medical innovations within the medical technology sector. It provides capital and support to entrepreneurs...
415 CAPITAL
415 Capital is a venture capital firm investing in medical innovations within the medical technology sector. It provides capital and support to entrepreneurs developing technologies addressing patient needs, particularly in cardio and neurovascular disorders. 415 Capital is based in Oberhaching, Germany, and has made 18 investments, including a Series C investment in Endovascular Engineering on April 07, 2026.
General information
Firm type
Private Equity
Year founded
2018
Location
Region
Europe
Country
Germany
City
Munich
Corporate office
Munich, Germany
Frequently asked questions
What is 415 CAPITAL's investment strategy?
415 CAPITAL pursues a venture and growth-stage investment strategy concentrated exclusively on the medical technology sector, with a specific emphasis on cardiovascular innovation. The firm invests from early seed rounds through to late-stage expansion, taking an active, direct equity approach.
What geographic markets does 415 CAPITAL target?
The firm is headquartered in Munich, Germany, and operates from this European base. While its primary strategic anchor is the European medical technology cluster, the firm's stage-agnostic mandate does not preclude cross-border investments within its narrow sector focus.
Does 415 CAPITAL operate as a single-family office or an institutional asset manager?
415 CAPITAL is structured as an asset manager with a private equity mandate. It is not a single-family office or multi-family office, but rather a specialized investment firm managing third-party capital through a dedicated venture and growth strategy.
Which sectors does 415 CAPITAL explicitly avoid?
The firm’s strategy is exclusively geared toward medical technology, specifically cardiovascular solutions. It implicitly avoids all sectors outside of medtech, such as enterprise software, consumer technology, or general industrial tech, maintaining a highly concentrated, single-sector playbook.
How does 415 CAPITAL source its proprietary deal flow?
The firm’s deep, single-sector focus on cardiovascular medtech is its primary sourcing advantage. By concentrating its network, research, and technical diligence within one niche, 415 CAPITAL aims to access opportunities through specialized clinical, academic, and industry channels in Europe rather than competing in broad, multi-sector auctions.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: